PTPA and cancer: Due to off-target effects of D2 dopamine receptor antagonism, phenothiazines could not be used therapeutically in cancer but provided the structural basis for the development of more specific PP2A activators: improved Heterocyclic Activators of PP2A (iHAPs) and Small Molecule Activators of PP2A (SMAPs) (168).